Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH.

Annals of hepatology - 1 Jan 2026

Jermy Bradley, Brownrigg Jack, Strnad Pavel, Loomba Rohit

Abstract excerpt

INTRODUCTION AND OBJECTIVES: Most investigational treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) show modest anti-fibrotic effects, likely due to a multifactorial aetiology. The Pi*Z mutation in SERPINA1 can lead to proteotoxic liver injury and progressive chronic liver disease. Here, we investigate whether the SERPINA1 Z...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antitrypsin
Share to alpha 1-Antitrypsin Deficiency

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease Progression

Share to Fatty Liver

Share to Liver Cirrhosis

Share to Phospholipases A2, Calcium-Independent

Share to Risk Factors

Share to United Kingdom

Source

Identifiers

PMID: 41135761
DOI: 10.1016/j.aohep.2025.102143

Genes

PNPLA3
SERPINA1
HSD17B13
TM6SF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 16 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alpha-1 antitrypsin Pi*MZ variant increases the risk of liver disease progression in MASLD and MASH.PMID 41135761Read ↗

Meta-Analysis: Redefining Liver Disease Risk in Heterozygous Alpha-1 Antitrypsin Deficiency.Semantic proximity Read ↗

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.Semantic proximity Read ↗

Genetic modulators of metabolic dysfunction-associated steatotic liver disease (MASLD) and their epistatic interactions: from in vitro and animal models to clinical outcomes.Semantic proximity Read ↗

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver DiseaseSemantic proximity Read ↗

Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi∗Z Variant of AAT (Pi∗MZ vs Pi∗ZZ genotype) and Noncarriers.Semantic proximity Read ↗

Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.Semantic proximity Read ↗

Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology.Semantic proximity Read ↗

Genetic Predisposition to MASLD: Potential for Therapeutic Management.Semantic proximity Read ↗

Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of MASLD.Semantic proximity Read ↗

Alpha-1 antitrypsin deficiency-associated liver disease: From understudied disorder to the poster child of genetic medicine.Semantic proximity Read ↗

Genetic and non-genetic drivers of histological progression and regression in MASLD.Semantic proximity Read ↗

Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction-Associated Steatotic Liver Diseases: A Pathway to Precision Medicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.